What DarouPakhsh Holding does

DarouPakhsh Holding Company (گروه داروپخش) is a publicly listed Iranian pharmaceutical investment holding company founded in 1957 and headquartered in Tehran. Originally established as a charitable institution, the company was nationalized in 1980, transferred to the Iranian Social Security Organization (SSO) in 1992, listed on the Tehran Stock Exchange in 1994, and converted to a holding structure in 1997 following the spin-off of its last manufacturing subsidiary. It operates as a subsidiary of Tamin Pharmaceutical Investment Company (TPICO), itself owned by the SSO (Shasta), giving the group a state-linked ownership chain. The holding manages a portfolio of subsidiaries covering the full pharmaceutical value chain: human-drug manufacturing (Karkhanat Daroupakhsh, Exir, Abu Reihan, Zahravi, Razak Laboratories), veterinary pharmaceutical production (Zagros Farmed Pars), biotechnology (Biodaro), pharmaceutical distribution (Tazeh Daroopakhsh with 24+ centers nationwide, plus dedicated veterinary and Exir-aligned distributors), and commercial trading (Daroupakhsh Commercial Expansion). Together these entities employ roughly 4,400 staff and produce more than 160 pharmaceutical product types across tablets, capsules, injectables, syrups, soft gels, oral suspensions, and biotech products, distributed under ISO and GMP-certified operations primarily to domestic pharmacies and healthcare providers.

The group's business model rests on three integrated revenue streams: (i) pharmaceutical manufacturing and sales through its subsidiary producers; (ii) distribution transaction fees from the nationwide wholesale network, which claims to be Iran's largest pharmaceutical distributor with a 70-year operating history; and (iii) holding-company income from dividends and returns on equity investments in those subsidiaries. Pricing is not publicly disclosed, and pharmaceutical pricing in Iran is regulated by the Food and Drug Organization. The go-to-market is sales-led and B2B: the group sells into pharmacies and institutional healthcare providers domestically, participates selectively in international exhibitions (Iran Expo 2025, International Poultry Veterinary Congress), and pursues exports and technology transfer. Consolidated group sales grew from 12,698 billion Rials in 1400 (2021) to 19,068 billion Rials in 1402 (2023), implying a ~22% CAGR, with several subsidiaries reporting 40–240% year-over-year sales growth in early 1404 (2025), indicating significant recent operating momentum under a new CEO appointed in mid-2024.

Name

DarouPakhsh Holding

Legal name

DarouPakhsh Holding Company (Public Joint-Stock Company)

Website

https://dpholding.com

Company type

Public

Founded year

1957

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

DarouPakhsh Holding is an Iranian pharmaceutical investment holding company managing the full pharma value chain — manufacturing, distribution, and trading — through subsidiaries serving pharmacies and healthcare providers across Iran, backed by TPICO and the Social Security Organization.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing and Distribution

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Pharmaceutical manufacturing
• Pharmaceutical distribution
• Veterinary pharmaceuticals
• Biotechnology medicines
• Pharmaceutical holding

Headquarters

HQ city

Tehran

HQ country

Iran

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Manufacturing and Sales: Revenue generated through the production and sale of pharmaceutical products (human and veterinary medicines) via subsidiary manufacturing companies.
2. Pharmaceutical Distribution Services: Revenue from distributing pharmaceutical products nationwide through the group's distribution subsidiaries.
3. Investment Holdings Income: As a holding/investment company, income is derived from dividends and returns on investments in subsidiary companies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

DarouPakhsh Holding is a publicly listed pharmaceutical investment holding company that manages a portfolio of subsidiaries spanning the full pharmaceutical value chain in Iran. Its subsidiaries manufacture human pharmaceuticals (over 160 product types in various dosage forms), veterinary medicines, biotechnology products, and raw pharmaceutical materials, and distribute these products through a nationwide network of 24+ distribution centers serving pharmacies and healthcare providers. The holding itself does not produce a unified consumer product but rather orchestrates and invests in manufacturing, distribution, and trading operations across its subsidiary companies.

Product overview

DarouPakhsh Holding is a publicly listed investment holding company that manages a portfolio of pharmaceutical subsidiaries covering the full value chain of Iran's pharmaceutical system — from active pharmaceutical ingredient production and drug manufacturing to distribution and commercialization. The holding structure comprises manufacturing companies (Karkhanat Daroupakhsh, Exir Pharmaceutical Manufacturing, Abu Rayhan, Zahravi, Razak Laboratories, and Zagros Farmed Pars), distribution companies (Distribution Daroupakhsh, Veterinary Drug Distribution, Exir Pharmaceutical Distribution, and the trading entity Daroupakhsh Commercial Expansion), and the biotech company Biodaro. The holding does not itself produce a unified software product; rather, it functions as a parent investment entity directing strategy across its subsidiaries, which collectively produce over 160 pharmaceutical product types in forms including tablets, capsules, injectables, syrups, soft gels, and oral suspensions, and distribute them through a nationwide network.

Differentiator

Problem solved

Functional benefit

Products and services

• DarouPakhsh Holding Company

Quantifiable outcome

• Revenue grew from 12,698 billion Rials (1400) to 19,068 billion Rials (1402), with 22% average annual growth rate
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators13 records

Recent moves10 records

Expansion highlights5 records

Broad incumbents

• Cipla: One of India's largest generic pharmaceutical manufacturers with global distribution; comparable as a large-scale branded/generic pharma manufacturer with vertical supply chain reach, although operating at much larger scale and across multiple geographies.
• Torrent Pharmaceuticals: India-based pharmaceutical manufacturer with branded generics and a domestic distribution network; structurally comparable to DarouPakhsh's combination of manufacturing scale plus domestic distribution, although at a different geography and larger scale.
• Cardinal Health: Major US pharmaceutical distributor and healthcare services company; relevant peer for DarouPakhsh's distribution subsidiary given the similar role of large-scale drug wholesaling to retail pharmacies and healthcare providers.
• Dr. Reddy's Laboratories: India-based global pharmaceutical manufacturer with strong generics and API portfolio; comparable to DarouPakhsh's manufacturing subsidiaries in producing branded and generic finished dosage forms across multiple therapeutic categories.
• Sun Pharmaceutical Industries: India's largest pharmaceutical company by revenue, with a broad specialty and generics manufacturing portfolio; comparable in scale and breadth of branded pharmaceutical manufacturing across multiple dosage forms.
• McKesson Corporation: The largest pharmaceutical distributor in the United States; comparable to DarouPakhsh's distribution arm (Distribution Daroupakhsh) which is described as Iran's largest pharma distributor, with similar large-scale wholesaler model supplying pharmacies and providers.

Direct peers

• Tamin Pharmaceutical Investment Company (TPICO): TPICO is DarouPakhsh's direct parent company and Iran's #1-ranked pharmaceutical holding group (ranked 1st in pharma, above DarouPakhsh's #2 rank in the IMI-100). It owns a portfolio of pharma manufacturers and distributors with the same integrated model, making it the closest structural peer.
• Barakat Pharmaceutical Group: Iranian pharmaceutical group with a portfolio of manufacturing and biotech subsidiaries; DarouPakhsh's CEO previously served as Deputy of Barekat Pharmaceutical Town, indicating overlapping operating model and competitive positioning in Iran's domestic pharma market.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/darou-paksh-pharmaceutical-holding-company

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DarouPakhsh Holding